Suppr超能文献

迟发性呕吐:发生率、模式、预后因素及最佳治疗方法。

Delayed emesis: incidence, pattern, prognostic factors and optimal treatment.

作者信息

Roila Fausto, Donati Donatella, Tamberi Stefano, Margutti Guido

机构信息

Medical Oncology Division, Arcispedale S. Anna, Ferrara, Italy.

出版信息

Support Care Cancer. 2002 Mar;10(2):88-95. doi: 10.1007/s005200100295. Epub 2001 Aug 23.

Abstract

Delayed emesis has been arbitrarily defined as vomiting and/or nausea beginning, or persisting for, more than 24 h after chemotherapy administration. Acute emesis is the most important prognostic factor for delayed emesis. Owing to the relatively high incidence and severity all patients treated with cisplatin > or = 50 mg/m(2) should receive antiemetic prophylaxis. In these patients a combination of dexamethasone plus metoclopramide or a 5-HT3 antagonist is the most efficacious regimen. All patients submitted to moderately emetogenic chemotherapy, such as cyclophosphamide, carboplatin, doxorubicin and epirubicin, should also receive antiemetic prophylaxis with oral dexamethasone to prevent delayed emesis.

摘要

迟发性呕吐被随意定义为化疗给药后24小时后开始出现或持续存在的呕吐和/或恶心。急性呕吐是迟发性呕吐最重要的预后因素。由于发病率和严重程度相对较高,所有接受顺铂剂量≥50mg/m²治疗的患者均应接受止吐预防。对于这些患者,地塞米松加甲氧氯普胺或5-羟色胺3拮抗剂联合使用是最有效的方案。所有接受中度致吐性化疗(如环磷酰胺、卡铂、阿霉素和表柔比星)的患者也应口服地塞米松进行止吐预防,以防止迟发性呕吐。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验